GENOCEA BIOSCIENCES, INC. - 10-K filing on 2020-02-13

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Total	Secondary public offering	Employee stock purchase plan	Common Shares	Common Shares Secondary public offering	Common Shares Employee stock purchase plan	Preferred Shares	Preferred Shares Secondary public offering	Additional Paid-In Capital	Additional Paid-In Capital Secondary public offering	Additional Paid-In Capital Employee stock purchase plan	Accumulated Deficit
Balance - Stockholders' Equity (Deficit) at Dec. 31, 2017	$ (6,050)			$ 3					$ 258,140			$ (264,193)
Balance - Stockholders' Equity (Deficit) (in shares) at Dec. 31, 2017				3,592			0
Increase (Decrease) in Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity
Issuance of common stock		$ 38,786	$ 67		$ 8					$ 38,077	$ 67
Issuance of common stock (in shares)					7,230	25		701
Stock-based compensation expense	2,153								2,153
Issuance of warrants in connection with debt modification	190								190
Net loss	(27,811)											(27,811)
Balance - Stockholders' Equity (Deficit) at Dec. 31, 2018	7,335			$ 11					298,627			(292,004)
Balance - Stockholders' Equity (Deficit) (in shares) at Dec. 31, 2018				10,847			701
Increase (Decrease) in Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity
Issuance of common stock		$ 54,669	$ 130		$ 16					$ 54,653	$ 130
Issuance of common stock (in shares)					16,530	71
Exercise of stock options	21								21
Exercise of stock options (in shares)				5
Stock-based compensation expense	1,837								1,837
Net loss	(38,950)											(38,950)
Balance - Stockholders' Equity (Deficit) at Dec. 31, 2019	$ 25,042			$ 27					$ 355,268			$ (330,954)
Balance - Stockholders' Equity (Deficit) (in shares) at Dec. 31, 2019				27,453			701